The SAM peripheral vascular devices market is expected to grow from US$ 894.09 million in 2021 to US$ 1,228.74 million by 2028; it is estimated to register a CAGR of 4.6% from 2021 to 2028. The three most common CVDs across the region are coronary heart disease, cerebrovascular disease, and peripheral artery disease. Although cardiovascular disease prevention and control has gained traction in recent decades, efforts have primarily focused on coronary heart disease and cerebrovascular disease, the world's leading causes of mortality. Despite receiving less attention, peripheral artery disease has emerged as a significant contributor to the worldwide deaths and disabilities, with an increasing burden in low-income and middle-income countries (LMICs). A blockage in the blood vessels causes peripheral arterial disease (PAD) or peripheral vascular disease (PVD), which reduces blood flow to the limbs, most commonly the legs. An arterial embolism occurs when a mass of tissue or a foreign substance moves through the vascular tree and lodges in a distant artery, blocking blood flow. Ischemia, organ failure, and possible infarction result from this blockage. Medical and surgical emergencies, such as stroke, acute limb ischemia, mesenteric ischemia, and renal failure, are symptoms of this complex condition. Due to pre-existing factors, such as age, hypercoagulability, cardiac abnormalities, and atherosclerotic disease, surgical and intensive care patients are at a higher risk for arterial embolization. These factors are supporting the peripheral vascular devices market substantially across the region.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the SAM peripheral vascular devices market at a notable CAGR during the forecast period.
SAM Peripheral Vascular Devices Market Segmentation
The SAM peripheral vascular devices market is segmented into product, end user, and country. Based on product, the SAM peripheral vascular devices market is segmented into peripheral vascular stents, peripheral transluminal angioplasty balloon catheters, PTA guidewires, atherectomy devices, chronic total occlusion devices, aortic stents, synthetic surgical grafts, and embolization guidewires. Further, the peripheral vascular stents segment dominated the market in 2021. Based on end user, the SAM peripheral vascular devices market is segmented into hospitals & clinics, ambulatory care centers, specialty clinics, and others. Further, the hospitals & clinics segment dominated the market in 2021. Based on country, the SAM peripheral vascular devices market is segmented into Brazil, Argentina, and the Rest of SAM. Further, Brazil dominated the market in 2021.
Abbott, B. Braun Melsungen AG, BD, Boston Scientific Corporation, Cardinal Health Inc, Cook Medical LLC, Edwards Lifesciences Corporation, Medtronic, Teleflex Incorporated, and Terumo Corporation are among the leading companies operating in the SAM peripheral vascular devices market.
Some of the leading companies are: